rat her2 protein  (Sino Biological)

Journal: Frontiers in Immunology

Article Title: Robust CD8 + T cell responses induced by an mRNA-LNP vaccine encoding rat HER2 extracellular domain confer prophylactic tumor protection

doi: 10.3389/fimmu.2026.1737558

Figure Lengend Snippet: mRNA-LNP vaccine development via integrated mechanism, preparation, and characterization. (A) Schematic of the mRNA-LNP vaccine mechanism. Intramuscularly injected mRNA-LNPs are delivered to DCs. The encoded antigen is expressed and processed through two major pathways: the immunoproteasome/MHC class I pathway activates CD8 + T cells, while the endosomal/MHC class II pathway activates CD4 + T cells. Activated CD4 + T cells provide help to B cells for antibody production, orchestrating a coordinated adaptive immune response. (B) Schematic microfluidic process of mRNA-LNPs preparation. (C) Plasmid map of rat HER2 ECD and rat HER2 ECD-IFNγ. (D) Agarose gel electrophoresis of plasmid and linearized plasmid DNA. (E) Agarose gel electrophoresis of transcribed mRNA and total mRNA for rat HER2 ECD and rat HER2 ECD-IFNγ. M, 1kb ladder; 1, Plasmids with rat HER2 ECD sequence and 2, rat HER2 ECD-IFNγ sequence; 3, Linearized plasmid DNA with rat HER2 ECD sequence and 4, rat HER2 ECD-IFNγ sequence; 5, Agarose gel electrophoresis images of transcribed mRNA and 6, total mRNA of rat HER2 ECD; 7, Agarose gel electrophoresis images of transcribed mRNA and 8, total mRNA of rat HER2 ECD-IFNγ.

Article Snippet: Splenocytes (2 × 10 5 cells/well) were stimulated in complete RPMI 1640 medium with or without 2 μg/mL rat HER2 protein (#80079-R08H, Sino Biological) for 12 hours at 37 °C.

Techniques: Bioprocessing, Injection, Plasmid Preparation, Agarose Gel Electrophoresis, Sequencing

Journal: Frontiers in Immunology

Article Title: Robust CD8 + T cell responses induced by an mRNA-LNP vaccine encoding rat HER2 extracellular domain confer prophylactic tumor protection

doi: 10.3389/fimmu.2026.1737558

Figure Lengend Snippet: Therapeutic efficacy of HER2 ECD mRNA-LNP vaccines in 4T1-HER2 tumor-bearing mice. (A) Treatment schedules and dosing intervals of the 4T1-HER2 tumor model. (B) Serum anti-HER2 antibody kinetics after 5 μg or 10 μg rHER2 ECD mRNA-LNP vaccination. (C) Changes in serum HER2 antibody concentration over time after administration after rHER2 ECD mRNA-LNP or rHER2 ECD-IFNγ mRNA-LNP vaccination. (D) Growth curve of 4T1-HER2 tumors. (E) Representative images of tumor volume. N = 3. Data are presented as mean ± standard error of the mean (SEM); two-sided t-test. (* P < 0.05 and *** P < 0.001).

Article Snippet: Splenocytes (2 × 10 5 cells/well) were stimulated in complete RPMI 1640 medium with or without 2 μg/mL rat HER2 protein (#80079-R08H, Sino Biological) for 12 hours at 37 °C.

Techniques: Drug discovery, Vaccines, Concentration Assay

Journal: Frontiers in Immunology

Article Title: Robust CD8 + T cell responses induced by an mRNA-LNP vaccine encoding rat HER2 extracellular domain confer prophylactic tumor protection

doi: 10.3389/fimmu.2026.1737558

Figure Lengend Snippet: Safety profiles of HER2 ECD mRNA-LNP vaccines in 4T1-HER2 tumor-bearing mice. (A) Body, heart, liver and lung weights of mice. (B) Hepatic function, renal function and cardiac function on day 68. N = 3. Data are presented as mean ± SEM; two-sided t-test. No significant intergroup differences were observed.

Article Snippet: Splenocytes (2 × 10 5 cells/well) were stimulated in complete RPMI 1640 medium with or without 2 μg/mL rat HER2 protein (#80079-R08H, Sino Biological) for 12 hours at 37 °C.

Techniques: Vaccines

Journal: Frontiers in Immunology

Article Title: Robust CD8 + T cell responses induced by an mRNA-LNP vaccine encoding rat HER2 extracellular domain confer prophylactic tumor protection

doi: 10.3389/fimmu.2026.1737558

Figure Lengend Snippet: Memory T cell subsets and antitumor activity. (A) Representative flow cytometry plots of T CM cells (CD44 + CD62L + ), T EM cells (CD44 + ) and naive cells (CD44 - CD62L + ) within CD4 + and (B) CD8 + T cells. (C) Rate of inhibition of 4T1-HER2 cells by vaccinated mouse splenic lymphocytes. (D) Concentration of IFNγ antibody in serum after administration. N = 3. Data are presented as mean ± SEM; two-sided t-test. (* P < 0.05, ** P < 0.01, and *** P < 0.001).

Article Snippet: Splenocytes (2 × 10 5 cells/well) were stimulated in complete RPMI 1640 medium with or without 2 μg/mL rat HER2 protein (#80079-R08H, Sino Biological) for 12 hours at 37 °C.

Techniques: Activity Assay, Flow Cytometry, Inhibition, Concentration Assay

Journal: Frontiers in Immunology

Article Title: Robust CD8 + T cell responses induced by an mRNA-LNP vaccine encoding rat HER2 extracellular domain confer prophylactic tumor protection

doi: 10.3389/fimmu.2026.1737558

Figure Lengend Snippet: Antitumor efficacy of combination therapy. (A) Treatment schedules and dosing intervals of the 4T1-HER2 tumor model. (B) Changes in serum HER2 antibody concentration over time after administration after rHER2 ECD mRNA-LNP vaccination, with and without anti-PD-1. (C) Growth curve of 4T1-HER2 tumors. (D) Representative images of tumor tissue. (E) Tumor volume. N = 6;Data are presented as mean ± SEM. Two-sided t-test. (* P < 0.05 and *** P < 0.001).

Article Snippet: Splenocytes (2 × 10 5 cells/well) were stimulated in complete RPMI 1640 medium with or without 2 μg/mL rat HER2 protein (#80079-R08H, Sino Biological) for 12 hours at 37 °C.

Techniques: Concentration Assay